Redcare Pharmacy: A Binding Ad Ban and a Double-Edged Reform Weigh on a Beaten-Down Stock

Redcare Pharmacy's Q1 prescription sales surged 55% but a court ruling restricts advertising and a new reform bill adds costs, pressuring margins amid 50% stock decline.

The stock of Redcare Pharmacy has been cut in half over the past year, yet the underlying prescription business is roaring ahead. In the first quarter, German Rx revenue surged 55%, helping the company post 18.4% group sales growth to €849.5 million and a 58% jump in adjusted EBITDA to €14.4 million. The market, however, is fixated on two structural headwinds that have arrived in quick succession: a legally binding court order restricting how the company can advertise, and a pharmacy reform bill that could boost demand but also impose new compliance costs.

Cologne court clips marketing language

On 23 April 2026, the Landgericht Köln ruled against a Facebook advertisement run by Shop Apotheke, one of Redcare’s core brands. The slogan promised “personal advice, drug interaction checks, and everything that makes a real pharmacy.” The court deemed it misleading. Shop Apotheke chose not to appeal, making the verdict final and enforceable. While the ruling does not block electronic prescription processing or platform operations, it tightens the boundaries for how online pharmacies describe their services — a sensitive issue for a company that has built its growth narrative around the e?prescription opportunity.

Margin squeeze deepens as competition heats up

The legal setback comes at a time when Redcare’s profitability is already under pressure. Gross margin slipped to 21.0% in the first quarter, down from 23.3% a year earlier and marginally below the 21.2% recorded in the fourth quarter of 2025. Management attributes the decline to intense competition in the over?the?counter segment, a rising share of low?margin prescription business, and a prescription bonus introduced in September 2025. The full?year target for adjusted EBITDA margin remains at least 2.5%, which would require a sharp improvement from the 1.7% level seen in Q1. Achieving that hinges on a stronger second half.

On the OTC front, the competitive landscape is becoming more crowded. Drugstore chain dm launched its own platform, “dm?med”, at the end of 2025, and Rossmann has announced plans to build an online pharmacy this year. Crucially, Rossmann intends to steer clear of prescription drugs — a structural buffer for Redcare’s Rx business, where it commands a 67% share of the German online market and expects to generate over €670 million in revenue for the full year. The steady erosion of brick?and?mortar pharmacies also plays in its favour: Germany ended 2025 with 16,601 physical pharmacies, roughly 440 fewer than a year earlier.

Pharmacy reform: opportunity and risk in one piece of legislation

The Bundestag passed the “Apothekenversorgung-Weiterentwicklungsgesetz” on 22 May 2026, with the votes of the CDU/CSU and SPD. The law is scheduled to take effect in the summer. For Redcare, every pharmacy closure channels more prescription volume into digital channels — a direct tailwind. But earlier drafts also included stricter requirements on contracts, documentation, and temperature control during transport, which would raise costs for mail?order operators. The final text now awaits approval by the Bundesrat, and the market has priced in the uncertainty. The stock’s 12?month decline of 62% reflects that ambivalence.

Analysts hold the line despite the share price rout

Despite the 35% year?to?date drop, the analyst community remains largely bullish. Seven out of nine analysts rate the stock a buy, two recommend holding, and none suggest selling. The average price target stands at roughly €95. Jefferies is the most optimistic at €150, citing the e?prescription dynamic, while UBS is the most cautious at €74, warning of a slowdown in the core OTC business. Deutsche Bank, Berenberg, and Baader Bank have all reiterated their buy calls since the first?quarter numbers were published. At the recent “dbAccess European Champions Conference”, Deutsche Bank analyst Jan Koch reaffirmed a target of €99, arguing that the current share price of around €44 already reflects the valuation of comparable high?growth online retailers.

Two key dates loom

The half?year report is scheduled for 29 July 2026. It will show whether margin trends have reversed and whether the EBITDA target for the full year remains within reach. Until then, the Bundesrat’s verdict on the pharmacy reform — expected shortly after the summer break — will hang over the stock. If the new rules prove net positive, Redcare’s dominant Rx position could finally drag the share price out of its slump. If not, the dual weight of a binding ad ban and tighter compliance costs will push the margin recovery further into the distance.